tbuckley/cabot-search huggingface dataset:
Markhor-derived Introgression of a Genomic Region Encompassing<i>PAPSS2</i>Confers High-altitude Adaptability in Tibetan Goats
Authors: Chao Li, Yujiang Wu, Bingchun Chen, Yudong Cai, Jiazhong Guo, Alexander S Leonard, Peter Kalds, Shiwei Zhou, Jingchen Zhang, Ping Zhou, Shangqu Gan, Ting Jia, Tianchun Pu, Langda Suo, Yan Li, Ke Zhang, Lan Li, Myagmarsuren Purevdorj, Xihong Wang, Ming Li, Yu Wang, Yao Liu, Shuhong Huang, Tad Sonstegard, Ming-Shan Wang, Stephen Kemp, Hubert Pausch, Yulin Chen, Jian-Lin Han, Yu Jiang, Xiaolong Wang
Journal: Molecular Biology and Evolution (2022)

Abstract Understanding the genetic mechanism of how animals adapt to extreme conditions is fundamental to determine the relationship between molecular evolution and changing environments. Goat is one of the first domesticated species and has evolved rapidly to adapt to diverse environments, including harsh high-altitude conditions with low temperature and poor oxygen supply but strong ultraviolet radiation. Here, we analyzed 331 genomes of domestic goats and wild caprid species living at varying altitudes (high &amp;gt; 3000 m above sea level and low &amp;lt; 1200 m), along with a reference-guided chromosome-scale assembly (contig-N50: 90.4 Mb) of a female Tibetan goat genome based on PacBio HiFi long reads, to dissect the genetic determinants underlying their adaptation to harsh conditions on the Qinghai-Tibetan Plateau (QTP). Population genomic analyses combined with genome-wide association studies (GWAS) revealed a genomic region harboring the 3′-phosphoadenosine 5′-phosphosulfate synthase 2 (PAPSS2) gene showing strong association with high-altitude adaptability (PGWAS = 3.62 × 10−25) in Tibetan goats. Transcriptomic data from 13 tissues revealed that PAPSS2 was implicated in hypoxia-related pathways in Tibetan goats. We further verified potential functional role of PAPSS2 in response to hypoxia in PAPSS2-deficient cells. Introgression analyses suggested that the PAPSS2 haplotype conferring the high-altitude adaptability in Tibetan goats originated from a recent hybridization between goats and a wild caprid species, the markhor (Capra falconeri). In conclusion, our results uncover a hitherto unknown contribution of PAPSS2 to high-altitude adaptability in Tibetan goats on QTP, following interspecific introgression and natural selection.
Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial
Authors: Mark Loeb, Ambuj Roy, Hisham Dokainish, Antonio Dans, Lia M Palileo-Villanueva, Kamilu Karaye, Jun Zhu, Yan Liang, Fastone Goma, Albertino Damasceno, Khalid F Alhabib, Gerald Yonga, Charles Mondo, Wael Almahmeed, Arif Al Mulla, Vitheya Thanabalan, Purnima Rao-Melacini, Alex Grinvalds, Tara McCready, Shrikant I Bangdiwala, Salim Yusuf
Journal: The Lancet Global Health (2022)
Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Authors: Hayley A Thompson, Alexandra B Hogan, Patrick G T Walker, Peter Winskill, Issaka Zongo, Issaka Sagara, Halidou Tinto, Jean-Bosco Ouedraogo, Alassane Dicko, Daniel Chandramohan, Brian Greenwood, Matt Cairns, Azra C Ghani
Journal: The Lancet Global Health (2022)
The HIV and sexually transmitted infection syndemic following mass scale-up of combination HIV interventions in two communities in southern Uganda: a population-based cross-sectional study
Authors: M Kate Grabowski, Josephine Mpagazi, Stephen Kiboneka, Robert Ssekubugu, John Baptiste Kereba, Annet Nakayijja, Julius Tukundane, Jade C Jackson, Austin D Peer, Caitlin Kennedy, Godfrey Kigozi, Ronald M Galiwango, Yukari C Manabe, Larry W Chang, Sarah Kalibala, Ronald H Gray, Maria J Wawer, Steven J Reynolds, Aaron A R Tobian, David Serwadda, Charlotte A Gaydos, Joseph Kagaayi, Thomas C Quinn
Journal: The Lancet Global Health (2022)
Errors in Data Set and Effect Sizes for 1 Study Included in Meta-analysis of Delay Discounting as a Transdiagnostic Process in Psychiatric Disorders
Authors: Michael Amlung
Journal: JAMA Psychiatry (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Incorrect Data Placement
Authors: Angela Renne, Shuhan He, Jarone Lee
Journal: JAMA (2022)

Matthew T. James, MD, PhD; Bryan J. Har, MD, MPH; Benjamin D. Tyrrell, MD; Peter D. Faris, PhD; Zhi Tan, MSc; John A. Spertus, MD, MPH; Stephen B. Wilton, MD, MSc; William A. Ghali, MD, MPH; Merril L. Knudtson, MD; Tolulope T. Sajobi, PhD; Neesh I. Pannu, MD, SM; Scott W. Klarenbach, MD, MSc; Michelle M. Graham, MD
Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
Authors: Milja Hartikainen, Heidi Taipale, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Markku Lähteenvuo, Jari Tiihonen
Journal: JAMA Psychiatry (2022)

There are no medications approved by authorities for the treatment of amphetamine or methamphetamine dependence, and studies investigating the effectiveness of pharmacological treatments in hard outcomes, such as hospitalization and death, are lacking.
Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature
Authors: Jian-Xian Lin, Jun-Peng Lin, Zu-Kai Wang, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Guang-Tan Lin, Ze-Ning Huang, Ju-Li Lin, Hua-Long Zheng, Guo-Sheng Lin, Chang-Ming Huang, Chao-Hui Zheng
Journal: JAMA Surgery (2022)

The survival benefit of laparoscopic total gastrectomy combined with spleen-preserving splenic hilar lymphadenectomy (LSTG) for locally advanced proximal gastric cancer (APGC) without invasion into the greater curvature remains uncertain.To compare the long-term and short-term efficacy of LSTG (D2 + No. 10 group) and conventional laparoscopic total gastrectomy (D2 group) for patients with APGC that has not invaded the greater curvature.In this open-label, prospective randomized clinical trial, a total of 536 patients with clinical stage cT2 to 4a/N0 to 3/M0 APGC without invasion into the greater curvature were enrolled from January 2015 to October 2018. The final follow-up was on October 31, 2021. Data were analyzed from December 2021 to February 2022.Eligible patients were randomized to the D2 + No. 10 group or the D2 group.The primary outcome was 3-year disease-free survival (DFS). The secondary outcomes were 3-year overall survival (OS) and morbidity and mortality within 30 days after surgery.Of 526 included patients, 392 (74.5%) were men, and the mean (SD) age was 60.6 (9.6) years. A total of 263 patients were included in the D2 + No. 10 group, and 263 were included in the D2 group. The 3-year DFS was 70.3% (95% CI, 64.8-75.8) for the D2 + No. 10 group and 64.3% (95% CI, 58.4-70.2; P = .11) for the D2 group, and the 3-year OS in the D2 + No. 10 group was better than that in the D2 group (75.7% [95% CI, 70.6-80.8] vs 66.5% [95% CI, 60.8-72.2]; P = .02). Multivariate analysis revealed that splenic hilar lymphadenectomy was not an independent protective factor for DFS (hazard ratio [HR], 0.86; 95% CI, 0.63-1.16) or OS (HR, 0.81; 95% CI, 0.59-1.12). Stratification analysis showed that patients with advanced posterior gastric cancer in the D2 + No. 10 group had better 3-year DFS (92.9% vs 39.3%; P < .001) and OS (92.9% vs 42.9%; P < .001) than those in the D2 group. Multivariate analysis confirmed that patients with advanced posterior gastric cancer could have the survival benefit from No. 10 lymph node dissection (DFS: HR, 0.10; 95% CI, 0.02-0.46; OS: HR, 0.12; 95% CI, 0.03-0.52).Although LSTG could not significantly improve the 3-year DFS of patients with APGC without invasion into the greater curvature, patients with APGC located posterior gastric wall may benefit from LSTG.ClinicalTrials.gov Identifier: NCT02333721.
Errors in Figure 2
Authors: Justin Arnold, Andrzej Kozikowski
Journal: JAMA Dermatology (2022)

Zenas Z. N. Yiu, PhD; Gabrielle Becher, MD; Brian Kirby, MD; Philip Laws, MD; Nick J. Reynolds, MD; Catherine H. Smith, MD; Richard B. Warren, PhD; Christopher E. M. Griffiths, MD; BADBIR Study Group; Fiona Browne; Ian Evans; Elise Kleyn; Linda Lawson; Kathleen McElhone; Teena Mackenzie; Tess McPherson; Ruth Murphy; Caroline Owen; Eleanor Pearson; Josh Richards; Mark Lunt; David Burden; Oras Alabas; Simon Morrison; Shernaz Walton; Anthony Bewley; Shehnaz Ahmed; Lillie Turnbull Jones; Charlotte Symons; Jonathan Barker; Philip Hampton
Team-Based Digital Gamification to Improve Cardiovascular Health in Women With Hypertensive Disorders of Pregnancy
Authors: Zahra Aryan, Emily A. Gordon, Alfonso H. Waller
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Primary Prevention Management of Elevated Lipoprotein(a)
Authors: Anandita Agarwala, Christie Ballantyne, Neil J. Stone
Journal: JAMA Cardiology (2022)

A male individual in his 40s with a strong family history of atherosclerotic cardiovascular disease including premature cardiovascular events in multiple family members presents to your clinic to establish care for cardiovascular risk stratification. What would you do next?
Respective Effects of Helmet Pressure Support, Continuous Positive Airway Pressure, and Nasal High-Flow in Hypoxemic Respiratory Failure: A Randomized Crossover Clinical Trial
Authors: Luca S. Menga, Luca Delle Cese, Tommaso Rosà, Melania Cesarano, Roberta Scarascia, Teresa Michi, Daniele G. Biasucci, Ersilia Ruggiero, Antonio M. Dell’Anna, Salvatore L. Cutuli, Eloisa S. Tanzarella, Gabriele Pintaudi, Gennaro De Pascale, Claudio Sandroni, Salvatore Maurizio Maggiore, Domenico L. Grieco, Massimo Antonelli
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: The respective effects of positive end-expiratory pressure (PEEP) and pressure support delivered through the helmet interface in patients with hypoxemia need to be better understood. Objectives: To assess the respective effects of helmet pressure support (noninvasive ventilation [NIV]) and continuous positive airway pressure (CPAP) compared with high-flow nasal oxygen (HFNO) on effort to breathe, lung inflation, and gas exchange in patients with hypoxemia (PaO2/FiO2 ⩽ 200). Methods: Fifteen patients underwent 1-hour phases (constant FiO2) of HFNO (60 L/min), helmet NIV (PEEP = 14 cm H2O, pressure support = 12 cm H2O), and CPAP (PEEP = 14 cm H2O) in randomized sequence. Measurements and Main Results: Inspiratory esophageal (ΔPES) and transpulmonary pressure (ΔPL) swings were used as surrogates for inspiratory effort and lung distension, respectively. Tidal Volume (Vt) and end-expiratory lung volume were assessed with electrical impedance tomography. ΔPES was lower during NIV versus CPAP and HFNO (median [interquartile range], 5 [3-9] cm H2O vs. 13 [10-19] cm H2O vs. 10 [8-13] cm H2O; P = 0.001 and P = 0.01). ΔPL was not statistically different between treatments. PaO2/FiO2 ratio was significantly higher during NIV and CPAP versus HFNO (166 [136-215] and 175 [158-281] vs. 120 [107-149]; P = 0.002 and P = 0.001). NIV and CPAP similarly increased Vt versus HFNO (mean change, 70% [95% confidence interval (CI), 17-122%], P = 0.02; 93% [95% CI, 30-155%], P = 0.002) and end-expiratory lung volume (mean change, 198% [95% CI, 67-330%], P = 0.001; 263% [95% CI, 121-407%], P = 0.001), mostly due to increased aeration/ventilation in dorsal lung regions. During HFNO, 14 of 15 patients had pendelluft involving >10% of Vt; pendelluft was mitigated by CPAP and further by NIV. Conclusions: Compared with HFNO, helmet NIV, but not CPAP, reduced ΔPES. CPAP and NIV similarly increased oxygenation, end-expiratory lung volume, and Vt, without affecting ΔPL. NIV, and to a lesser extent CPAP, mitigated pendelluft. Clinical trial registered with clinicaltrials.gov (NCT04241861).
Association Between Loneliness and Postoperative Mortality Among Medicare Beneficiaries
Authors: Mary R. Shen, Pasithorn A. Suwanabol, Ryan A. Howard, Hsou Mei Hu, Deborah A. Levine, Kenneth M. Langa, Jennifer F. Waljee
Journal: JAMA Surgery (2022)

This cohort study uses data from the Health and Retirement Study and Medicare claims to examine the association between loneliness and postoperative mortality after elective vs nonelective surgery among older adults.
Errors in Text, Tables, and Figure
Authors: Zindel Segal
Journal: JAMA Psychiatry (2022)

Michael Amlung, PhD; Emma Marsden, BA; Katherine Holshausen, PhD; Vanessa Morris, BA; Herry Patel, BSc; Lana Vedelago, BA; Katherine R. Naish, PhD; Derek D. Reed, PhD; Randi E. McCabe, PhD
Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones
Authors: Ryan C. Augustin, Riyue Bao, Jason J. Luke
Journal: Clinical Cancer Research (2022)

Programmed cell death protein 1 (PD-1) is a well-known driver of immunosuppression and lymphocyte-associated disease progression. Increasing evidence suggests a tumor-intrinsic role for PD-1 in promoting chemoresistance via stem-like features. Moving forward, a recent study implies a novel antitumor mechanism for PD-1 inhibition. See related article by Rotolo et al., p. 621.
Treatment for Patients With Multifocal Intrahepatic Cholangiocarcinoma
Authors: Junwei Zhang, Ziyu Xun, Yiyao Xu
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Cardiac Troponin I–Interacting Kinase Affects Cardiomyocyte S-Phase Activity but Not Cardiomyocyte Proliferation
Authors: Sean P. Reuter, Mark H. Soonpaa, Dorothy Field, Ed Simpson, Michael Rubart-von der Lohe, Han Kyu Lee, Arthi Sridhar, Stephanie M. Ware, Nick Green, Xiaochun Li, Susan Ofner, Douglas A. Marchuk, Kai C. Wollert, Loren J. Field
Journal: Circulation (2022)

Identifying genetic variants that affect the level of cell cycle reentry and establishing the degree of cell cycle progression in those variants could help guide development of therapeutic interventions aimed at effecting cardiac regeneration. We observed that C57Bl6/NCR (B6N) mice have a marked increase in cardiomyocyte S-phase activity after permanent coronary artery ligation compared with infarcted DBA/2J (D2J) mice.
Running to Outcompete Metastasis
Authors: Marwa Zerhouni, Elena Piskounova
Journal: Cancer Research (2022)

The role of exercise in cancer progression is an emerging field of research, with intriguing evidence for physical activity playing an inhibitory role in cancer onset. In their recent publication, Sheinboim and colleagues demonstrate the impact of physical exercise on melanoma primary tumor growth and metastasis. They establish that physical exercise decreases metastatic spread, using both human epidemiologic data and in vivo models of melanoma metastasis. Systemic metabolic reprogramming of organs, induced by exercise, leads to a decrease in melanoma growth and progression as healthy organs are able to outcompete melanoma cells for nutrients. Exercise led to systemic metabolic changes in carbohydrate metabolism, glycolysis, and oxidative phosphorylation as well as mitochondrial biogenesis. Interestingly, the “metabolic shield” created by exercise could be reversed using the mTOR inhibitor rapamycin. This study highlights the importance of metabolic plasticity in metastasis and uncovers a direct link between systemic metabolic reprogramming and mTOR signaling. Overall, the study by Sheinboim and colleagues provides a more detailed understanding of the metastatic requirements in the context of energy and nutrient availability and the impact of exercise on cancer progression, highlighting novel opportunities for therapeutic intervention. See related article by Sheinboim et al., p. 4164
Children, Climate Justice, and Lessons From Puerto Rico
Authors: Gredia Huerta-Montañez, Aaron Bernstein
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes
Authors: Han Han, Ying Wang, Tongtong Li, Chengwu Feng, Catherine Kaliszewski, Yang Su, Yinfan Wu, Jian Zhou, Liang Wang, Geng Zong
Journal: Diabetes Care (2022)

OBJECTIVE People with type 2 diabetes may have insufficient or prolonged sleep that could accelerate cardiovascular disease (CVD) onset, but existing evidence from prospective studies has been limited. We examined the association of sleep duration with CVD incidence and mortality in this high-risk population. RESEARCH DESIGN AND METHODS This prospective study included 18,876 participants with type 2 diabetes in the UK Biobank who were free of CVD and cancer at baseline. Habitual sleep duration was obtained using a baseline questionnaire. Cox proportional hazards regression models were used to examine the association between sleep duration and CVD events. RESULTS During an average follow-up of 11.0–12.0 years, we documented 2,570 incident cases of atherosclerotic cardiovascular disease (ASCVD) and 598 CVD deaths. Compared with sleeping for 7 h/day, the multivariable-adjusted hazard ratios of ≤5 and ≥10 h/day were 1.26 (95% CI 1.08, 1.48) and 1.41 (1.16, 1.70) for incident ASCVD, 1.22 (0.99, 1.50) and 1.16 (0.88, 1.52) for coronary artery disease, 1.70 (1.23, 2.35) and 2.08 (1.44, 3.01) for ischemic stroke, 1.02 (0.72, 1.44) and 1.45 (1.01, 2.10) for peripheral artery disease, and 1.42 (1.02, 1.97) and 1.85 (1.30, 2.64) for CVD mortality. Similar results were observed in most sensitivity analyses that aimed to address potential reverse causation and in the joint analyses of sleep duration and metabolic control or diabetes severity status. CONCLUSIONS Short and long sleep durations were independently associated with increased risks of CVD onset and death among people with type 2 diabetes.